Abstract
Since its introduction in the late 1970s for the treatment of strabismus and blepharospasm, botulinum toxin (BoNT) has been increasingly used in the interventional treatment of several other disorders characterized by excessive or inappropriate muscle contractions. The use of this pluripotential agent has extended to a plethora of conditions including: focal dystonia; spasticity; inappropriate contraction in most sphincters of the body such as those associated with spasmodic dysphonia, esophageal achalasia, chronic anal fissure, and vaginismus; eye movement disorders; other hyperkinetic disorders including tics and tremors; autonomic disorders such as hyperhidrosis; genitourinary disorders such as overactive and neurogenic bladder, nonbacterial prostatitis and benign prostatic hyperplasia; and aesthetically undesirable hyperfunctional facial lines. In addition, BoNT is being investigated for the control of the pain, and for the management of tension or migraine headaches and myofascial pain syndrome. BoNT injections have several advantages over drugs and surgical therapies in the management of intractable or chronic disease. Systemic pharmacologic effects are rare; permanent destruction of tissue does not occur. Graded degrees of relaxation may be achieved by varying the dose injected; most adverse effects are transient. Finally, patient acceptance is high. In this paper, clinical experience over the last years with BoNT in urological impaired patients will be illustrated. Moreover, this paper presents current data on the use of BoNT to treat pelvic floor disorders.
Keywords: anus, pathology, physiopathology, surgery, autonomic nervous system diseases, benign prostatic hyperplasia, botulinum toxin, pharmacology, therapeutic use, constipation
Current Medicinal Chemistry
Title: Management of Bladder, Prostatic and Pelvic Floor Disorders with Botulinum Neurotoxin
Volume: 12 Issue: 3
Author(s): G. Maria, F. Cadeddu, D. Brisinda, F. Brandara and G. Brisinda
Affiliation:
Keywords: anus, pathology, physiopathology, surgery, autonomic nervous system diseases, benign prostatic hyperplasia, botulinum toxin, pharmacology, therapeutic use, constipation
Abstract: Since its introduction in the late 1970s for the treatment of strabismus and blepharospasm, botulinum toxin (BoNT) has been increasingly used in the interventional treatment of several other disorders characterized by excessive or inappropriate muscle contractions. The use of this pluripotential agent has extended to a plethora of conditions including: focal dystonia; spasticity; inappropriate contraction in most sphincters of the body such as those associated with spasmodic dysphonia, esophageal achalasia, chronic anal fissure, and vaginismus; eye movement disorders; other hyperkinetic disorders including tics and tremors; autonomic disorders such as hyperhidrosis; genitourinary disorders such as overactive and neurogenic bladder, nonbacterial prostatitis and benign prostatic hyperplasia; and aesthetically undesirable hyperfunctional facial lines. In addition, BoNT is being investigated for the control of the pain, and for the management of tension or migraine headaches and myofascial pain syndrome. BoNT injections have several advantages over drugs and surgical therapies in the management of intractable or chronic disease. Systemic pharmacologic effects are rare; permanent destruction of tissue does not occur. Graded degrees of relaxation may be achieved by varying the dose injected; most adverse effects are transient. Finally, patient acceptance is high. In this paper, clinical experience over the last years with BoNT in urological impaired patients will be illustrated. Moreover, this paper presents current data on the use of BoNT to treat pelvic floor disorders.
Export Options
About this article
Cite this article as:
Maria G., Cadeddu F., Brisinda D., Brandara F. and Brisinda G., Management of Bladder, Prostatic and Pelvic Floor Disorders with Botulinum Neurotoxin, Current Medicinal Chemistry 2005; 12 (3) . https://dx.doi.org/10.2174/0929867053363315
DOI https://dx.doi.org/10.2174/0929867053363315 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antileukotriene Treatment in Children with Asthma - New Patents
Recent Patents on Inflammation & Allergy Drug Discovery Purinergic Receptors and Pain
Current Pharmaceutical Design Modulation of Huntington’s Disease in Drosophila
CNS & Neurological Disorders - Drug Targets Ibogaine in the Treatment of Substance Dependence
Current Drug Abuse Reviews Hospital Exemption for Advanced Therapy Medicinal Products: Issue in Application in the European Union Member States
Current Stem Cell Research & Therapy Outcome of Newborns with Neonatal Seizures: Risk Factors and Predictors
Current Pediatric Reviews The Modulation of Pain by Metabotropic Glutamate Receptors 7 and 8 in the Dorsal Striatum
Current Neuropharmacology Janus Nano- and Microparticles as Smart Drug Delivery Systems
Current Pharmaceutical Biotechnology Clinical, Psychosocial and Family Characteristics of Suicide Attempts Among Greek Adolescents
Adolescent Psychiatry Using Small Molecule GSK3β Inhibitors to Treat Inflammation
Current Medicinal Chemistry Taste and Hypertension in Humans: Targeting Cardiovascular Disease
Current Pharmaceutical Design ET-18-OCH3 (Edelfosine): A Selective Antitumour Lipid Targeting Apoptosis Through Intracellular Activation of Fas / CD95 Death Receptor
Current Medicinal Chemistry Vitamins B1, B2, B3 and B9 – Occurrence, Biosynthesis Pathways and Functions in Human Nutrition
Mini-Reviews in Medicinal Chemistry Targeting Bacterial RNA Polymerase: Promises for Future Antisense Antibiotics Development
Infectious Disorders - Drug Targets Ginkgo biloba Extract 761: A Review of Basic Studies and Potential Clinical Use in Psychiatric Disorders
CNS & Neurological Disorders - Drug Targets Peroxisome Proliferator Activated Receptor Gamma Coactivator 1 Alpha: An Emerging Target for Neuroprotection in Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets L-Arginine Signalling Potential in the Brain: The Peripheral Gets Central
Recent Patents on CNS Drug Discovery (Discontinued) Extracorporeal Shock Wave Therapy for Calcific Tendonitis of the Rotator Cuff: A Review
Current Rheumatology Reviews Recent Patents Review on Intranasal Administration for CNS Drug Delivery
Recent Patents on Drug Delivery & Formulation Structural Basis for Binding of Aurora-A<sup>G198N</sup>- INCENP Complex: MD Simulations and Free Energy Calculations
Protein & Peptide Letters